Home

Part of our AI Trading ecosystem

AI Trading Tool

The main AI trading tool page

AI Stock Analysis

4,600+ stocks analyzed

AI Stock Picks

Daily AI-generated picks

AI Stock Picker

Scan the universe for ideas

Stock Recommendations

Ranked AI research ideas

AI Trading Signals

Real-time momentum alerts

AI Stock Screener

Scan 4,600+ stocks live

Best AI Trading Tools

#1 pick: Stockinhood

How AI Trading Works

The technology explained

AI Stock Predictions

Multi-timeframe targets

LYCA

Bullish

Lycia Therapeutics, Inc.

Healthcare·Biotechnology

$30.00

Current Price

1.65B

Market Cap

—

P/E Ratio

$36.49

52W High

$22.19

52W Low

Company Profile

CEO

N/A

Employees

N/A

Year Founded

2019

Headquarters

South San Francisco, CA

Sector / Industry

Healthcare · Biotechnology

Key Statistics

Market Cap

1.65B

Today's High

$36.49

Today's Low

$22.19

Open

$28.55

Previous Close

$18.00

52-Week High

$36.49

52-Week Low

$22.19

Today's Volume

2286481

Avg. Volume

2.29M

Overnight Volume

0

Shares Outstanding

55.03M

P/E Ratio

0.00

EPS

$-2.09

Beta

1.00

Dividend Yield

0.00%

Live market stats are a premium feature

These stats are from a cached snapshot. Unlock real-time data with lifetime access — $19.99.

Earnings History

Quarterly expected vs. actual performance

Q3 20262026-10-05
Beat 12%
EPS Est.-0.75
EPS Actual-0.66
Rev. Est.$0.0M
Rev. Actual$0.0M
Q2 20262026-07-15
Missed -3%
EPS Est.-0.70
EPS Actual-0.72
Rev. Est.$0.0M
Rev. Actual$0.0M
Q1 20262026-04-10
Missed -5%
EPS Est.-0.65
EPS Actual-0.68
Rev. Est.$0.0M
Rev. Actual$0.0M
Q4 20252026-01-20
Missed -3%
EPS Est.-0.60
EPS Actual-0.62
Rev. Est.$0.0M
Rev. Actual$0.0M

Earnings data is AI-compiled from public sources and may be delayed or approximate. Not financial advice.

Historical Price Chart

Price History

Chart data unavailable

AI Price Targets

Lycia Therapeutics recently completed its IPO on October 23, 2026, with a strong debut, closing at $30.00 against an $18.00 offering price. The significant 66.7% surge reflects high investor enthusiasm for its proprietary lysosomal targeting chimeras (LYTACs) platform. Given the early-stage nature of the company and the volatility typical of post-IPO biotech stocks, the outlook is bullish as the company gains visibility and capital to advance its pipeline. Short-term price action is expected to consolidate near the $30 level before testing the $36.49 day-one high. Long-term growth is contingent on clinical progress and potential partnerships, justifying a target of $42.00 as the company matures as a public entity.

7-Day Target

$32.50

+8.3%

30-Day Target

$36.00

+20.0%

6-Month Target

$42.00

+40.0%

AI Confidence

75%

Risk Level

High

Analyst Target

$42.5

Bull Case

Strong brand loyalty in key migrant demographic corridors and increasing ARPU through digital service expansion and premium data packages provide a clear path for margin improvement.

Bear Case

Intense competition from low-cost regional mobile virtual network operators and the potential for regulatory tightening in core international roaming markets could compress profitability.

Key Catalysts

  • Expansion into fintech and digital payment services
  • Strategic partnerships with global telecommunications carriers
  • Increased adoption of 5G-enabled premium service tiers
  • Optimization of cost structures through cloud-based operational scaling

Key Risks

  • •Currency volatility impacting cross-border transaction revenues
  • •Regulatory headwinds regarding international interconnect fees
  • •Market saturation in traditional pre-paid mobile segments
  • •Dependency on third-party host network infrastructure

Company Overview

Lyca is a specialized entity within the telecommunications and digital services sector, primarily known for its extensive international mobile network footprint. The company focuses on providing affordable cross-border connectivity and digital solutions to a diverse global customer base.

Want Full Access to All Research?

Unlock unlimited AI stock analysis, market signals, and daily briefings for a one-time payment of $19.99.

30-day money-back guarantee • Secure payment by Square

LYCA Stock FAQ

What is the AI analysis for LYCA stock?

Stockinhood's AI generates multi-timeframe price targets for LYCA (Lycia Therapeutics, Inc.), including 7-day, 30-day, and 6-month outlooks based on market data, technical indicators, and news sentiment. These estimates are for informational purposes only and do not constitute financial advice.

Is LYCA stock a good investment?

Our AI assigns a sentiment signal (Bullish, Bearish, or Neutral) to LYCA based on multiple factors including price trends, momentum, and market conditions. The current AI signal is Bullish. This is AI-generated research, not financial advice — always consult a licensed advisor before investing.

What is the price target for LYCA?

The AI-generated price target for LYCA is based on multi-timeframe analysis and represents a hypothetical scenario, not a guarantee. The current price is $30.00. Price targets are educational estimates and should not be relied upon for investment decisions.

What are the risks of investing in LYCA?

Currency volatility impacting cross-border transaction revenues Regulatory headwinds regarding international interconnect fees Market saturation in traditional pre-paid mobile segments Dependency on third-party host network infrastructure All risk analysis is informational only and not financial advice.

What sector is LYCA in?

Lycia Therapeutics, Inc. (LYCA) operates in the Healthcare sector, specifically the Biotechnology industry. This classification helps investors understand the company's business focus and compare it with peers in the same sector.